Remodulin

DRUG3 trials

Sponsors

University of California, Los Angeles, United Therapeutics, Shanghai Jiao Tong University School of Medicine

Conditions

Congenital Heart DiseasePulmonary Arterial HypertensionPulmonary Hypertension

Phase 3

Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery

CompletedNCT02865733

Shanghai Jiao Tong University School of MedicinePulmonary Hypertension

Start: 2016-08-01End: 2019-08-20Updated: 2020-10-28

Phase 4

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

CompletedNCT02847260

United TherapeuticsPulmonary Arterial Hypertension

Start: 2012-04-30End: 2014-03-31Updated: 2017-10-17

Unknown Phase

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

WithdrawnNCT01980979

University of California, Los AngelesCongenital Heart Disease

Start: 2013-11-30End: 2015-12-31Updated: 2017-09-21

Related Papers

Pharmacokinetics of treprostinil in children with functional single-ventricle pulmonary arterial hypertension: a randomized controlled trial

Annals of Translational Medicine2021-07-0111 citations